SAO PAULO (Reuters) - Canada's Knight Therapeutics Inc GUD.TO and shareholders of Biotoscana Investments GBIO33.SA expect to conclude transfer of control of the Latin American pharmaceutical company by Nov. 29, the latter said in a securities filing on Monday.
Knight will spend 596 million reais ($149 million) for 51.2% of Biotoscana. After the acquisition, the Canadian company will offer the same price, 10.96 reais per share, to minority shareholders.
The total deal value is expected to reach 1.16 billion reais, or 1.3 billion if Biotoscana’s debt is included, the company added. ($1 = 3.9902 reais)
Reporting by Tatiana Bautzer; Editing by Muralikumar Anantharaman
Our Standards: The Thomson Reuters Trust Principles.